• Buy these ASX dividend shares if the RBA cuts rates

    Cut interest rates

    This afternoon the Reserve Bank will hold its August meeting and make a decision on the cash rate.

    Although there is a small chance of a rate cut to zero, it looks reasonably unlikely based on the latest cash rate futures.

    While this is a small win for income investors, it doesn’t make much of a difference in the grand scheme of things. Whether or not there is a cut today, interest rates will still be at ultra-low levels.

    In light of this, I would suggest income investors continue to look beyond savings accounts and term deposits. Instead, I think they should be focusing on some of the quality dividend shares trading on the Australian share market.

    Two ASX dividend shares that I would buy are listed below.

    Dicker Data Ltd (ASX: DDR)

    The first ASX dividend share to consider buying is Dicker Data. It is a leading wholesale distributor of computer hardware and software across the ANZ region. Dicker Data has been a very positive performer over the last few years and this has continued in FY 2020. It recently reported stellar growth during its recently completed first half. Dicker Data reported half year revenue above $1 billion for the first time and a 30.4% lift in net profit before tax to $42 million. In light of this, the company is on course to increase its dividend by 31% to 35.5 cents per share this year. Based on the current Dicker Data share price, this represents a generous fully franked 4.75% dividend yield.

    Rural Funds Group (ASX: RFF)

    Another ASX dividend share to consider buying is Rural Funds. I think the agriculture-focused property group is a great option for income investors due to the quality and diversity of its portfolio. Another positive is the long tenancy agreements of its assets, which I believe puts Rural Funds in a position to continue growing its distribution during the pandemic and for many years to come. The company recently reaffirmed its distribution guidance of 10.85 cents per share in FY 2020 and then 11.28 cents per share in FY 2021. Based on the latest Rural Funds share price, the latter equates to a 5.5% yield.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Dicker Data Limited and RURALFUNDS STAPLED. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Buy these ASX dividend shares if the RBA cuts rates appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3i2MpEp

  • Should you invest in Commonwealth Bank shares?

    Businessman smashing white piggybank with hammer

    The big four Australian bank shares enjoy a unique space in our economy. In part, this is due to Paul Keating’s 4 Pillars policy, originally 6 Pillars. A policy that prevents them from taking over one another.

    However, a foreign bank or company could take over any one of them. One of the results of this policy is that they are all in the top 30 of the world’s largest banks by market capitalisation. In fact, the price of  Commonwealth Bank of Australia (ASX: CBA) shares makes it the 13th largest bank in the world by market cap.

    As the coronavirus pandemic rages on, it has become clear just how important our banks are. They have proven to be one of the nation’s great economic weapons. When used in conjunction with our superannuation system, they have cushioned the short term blow of the pandemic. In fact, to an outsider, the banks must appear as if they were an arm of government. 

    Given their intrinsic importance to the economic well-being of the country, I wonder if they are still a good investment. Or, does their national role prevent that?

    Banks and the pandemic

    The banks are regulated by the The Australian Prudential Regulation Authority (APRA). This regulator is charged with maintaining a “stable, efficient and competitive financial system” via prudential standards and practices. This is where it all gets interesting for me. Moreover, we saw this in action during the early stages of the lockdown.

    APRA allowed the banks to provide a range of assistance. First, it allowed a loan repayment deferral period of up to 6 months without being in arrears. This is part of the support available to small business also.

    Second, it allowed banks to extend or change the type of loan without serviceability assessments. For example, a mortgage change from principal and interest, to interest only. Under the APRA guidelines, this can happen without having to prove it can be paid for.

    To help the banks further, the regulator requested that they “limit discretionary capital distributions in the months ahead”. Instead, asking them to maintain a buffer to potentially support the economy. This meant no dividend payments. 

    At the time of writing, APRA has extended this from 6 months to 10 months, or until 31 March 2021, whichever comes first.  In addition, it has changed its advice on dividends. Effectively capping them at a maximum of 50% of profits. I think these factors are holding down the price of Commonwealth Bank shares.

    The impact on Commonwealth Bank shares

    The basic business model of a bank is arbitrage. That is, take in funds at a specific short-term interest rate, and then loan it out for longer terms at higher interest rates. Banks have already agreed to a 6-month deferral of loan repayments, and are likely to be under massive pressure to extend for the full 10 months. This is a major hole in revenues.

    Additionally there is the risk of loan defaults. Over the past 5 years, the average number of companies to declare themselves insolvent is about 600 per month. However, according to TradingEconomics.com, only slightly more than 400 companies have become insolvent during April and May.

    Moreover, we can see rising unemployment and the gradual winding down of JobKeeper. It is clear to me that there is going to be a tidal wave of defaults in both business and personal loans.

    CommBank is the largest provider of home loans and business loans in Australia, therefore likely carrying the most risk of defaults. This is just one of the potential consequences of the interests of the nation overriding the interest of the shareholders. It may well be the right thing to do, or even the ethical thing to do. Nonetheless, that doesn’t make it in the best interests of the shareholders.

    Could Commonwealth Bank shares grow?

    There is a reason why banks are often seen as lumbering, overly cautious enterprises. Of the four major banks, only CommBank has a large, successful international operation. In addition, unlike the other banks, it is the only one to make a move into the buy now pay later (BNPL) sector via its deal with Swedish bank Klarna. However, across all of the bank’s traditional verticals there are piranhas nipping at its heels. 

    For example, CommBank is the nation’s largest provider of digital payments services. Nevertheless, companies like Tyro Payments Ltd (ASX: TYR) are making solid inroads into national market share. Tyro has set itself up as the largest EFTPOS provider among all authorised deposit taking institutes (ADI) outside of the big four banks. Moreover, credit cards are under fire by other BNPL companies such as  Afterpay Ltd (ASX: APT) and Zip Co Ltd (ASX: Z1P).

    In loans, the bank is under fire from start ups like WISR Ltd (ASX: WZR), as well as a range of neo-banks mostly dedicated to having only an online presence. Companies like Moneyme Ltd (ASX: MME) or the private Judo Bank. In addition, debtor finance is becoming more of a respectable mechanism to access short term funds. This includes companies like CML Group Ltd (ASX: CGR).

    Foolish Takeaway

    I strongly believe that if the 4 Pillars policy didn’t exist, at least one, maybe more, of the large banks would have disappeared. Therefore, if I had to invest in any bank equities, it would be in Commonwealth Bank shares. However, it would be primarily for the possibility of moderate share price growth. Nevertheless, there is no way I am going to invest in any banks at present.

    The ability of the regulator to direct a bank to take actions potentially detrimental to shareholders adds a level of risk. Moreover, the banks now have their dividends effectively capped. So the main reason why many investors held them in the first place has disappeared.

    Lastly, as we emerge from coronavirus, it is clear that the banks still have a lot of bad news ahead of them. Meanwhile, competitors are actively slicing away market share in various areas. There are many other opportunities on the ASX if you are willing to do the work to find them. 

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Daryl Mather has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Tyro Payments and ZIPCOLTD FPO. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Should you invest in Commonwealth Bank shares? appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2PmCVrC

  • Sorrento’s New COVID-19 Test Could Be a Game Changer, Says 5-Star Analyst

    Sorrento’s New COVID-19 Test Could Be a Game Changer, Says 5-Star AnalystSorrento Therapeutics (SRNE) enjoyed yet another stellar day. Sure, there have been plenty of good weeks so far in 2020 – shares are up by a resounding 190% year-to-date. And according to H.C. Wainwright analyst Ram Selvaraju, there’s plenty more to come.Selvaraju reiterated a Buy rating on SRNE shares and boosted his price target to $30. If the market plays nice with Selvaraju’s forecast, investors could be adding a massive 207% to their portfolios over the next 12 months. (To watch Selvaraju’s track record, click here)That’s an extremely bullish call, so what lies behind it? Last week, Sorrento announced it had inked a licensing deal with Columbia University for an innovative new COVID-19 test. The university has given Sorrento the rights to a fast, one-step diagnostic test that samples saliva and can detect the SARS-CoV-2 virus in 30 minutes.COVI-TRACE – the test’s name – will be marketed by Sorrento. What sets it apart from other diagnostic products is that all testing materials are held in a single tube, eliminating the need for any laboratory equipment. The advantages are obvious, as this means the test is mobile and can be used in various settings – either on site, for point-of-care or even for home testing.With the number of COVID-19 cases spiking, laboratories across the country are finding it difficult to meet the demand. As a result of the current backlog, average turnaround times for test results are reportedly between several days to over a week. Selvaraju expects Sorrento to file for EUA certification immediately. The 5-star analyst said, “We believe that the incentive to facilitate the large-scale and indeed ubiquitous deployment of the COVI-TRACE test is extremely high and governments worldwide may seek to implement this in their respective regions. Our current assumptions viewed in this context may be considered conservative—we utilize a $15 price per test (payable on a cash basis, which obviates the reimbursement part of the equation) and anticipate that roughly 56.5 million such tests could be conducted at peak annually, resulting in total sales of roughly $1 billion."Overall, only one other analyst has thrown the hat in with a review of the high-flying biotech over the past three months. The extra Buy provides Sorrento with a Moderate Buy consensus rating. At $27, the average price target implies upside potential of 181%. (See Sorrento stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

    from Yahoo Finance https://ift.tt/3gwChDS

  • Virgin Galactic reports no quarterly revenue, plans additional offering of 20.5M in shares

    Virgin Galactic reports no quarterly revenue, plans additional offering of 20.5M in sharesShares of Virgin Galactic Holdings slipped as much as 9% on Monday following the release of its second-quarter results, which fell below investors’ expectations. The company announced that it would be offering an additional 20.5 million in shares to raise about $460 million. Yahoo Finance’s Jared Blikre breaks down the company’s quarterly report on The Final Round.

    from Yahoo Finance https://ift.tt/3k9RGvO

  • Moderna Analyst: Phase 3 Coronavirus Data Could Arrive As Soon As October

    Moderna Analyst: Phase 3 Coronavirus Data Could Arrive As Soon As OctoberModerna Inc (NASDAQ: MRNA) initiated a large-scale Phase 3 study of its coronavirus vaccine candidate in mid-July.An analyst at Jefferies conducted a statistical analysis of the study design to arrive at the likely timing of the data readout — whether they think the study will achieve statistical significance.The Moderna Analyst: Michael Yee has a Buy rating on Moderna with a $90 price target. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.The Moderna Thesis: Fast enrollment and the above-average infection rate in hot spots will drive a 70% probability of Moderna having preliminary late-stage data by October/November, Yee said in a Monday note. (See his track record here.)"Based on our statistical model, we could be in for a 'Halloween Treat' with data achieving statistical significance potentially as early as October," the analyst said.The company's Phase 3 study has a 65% chance of working, with an October readout followed by Emergency Use Authorization by end of 2020, in his view. These catalytic events could pave the way for the unlocking of multi-billion-dollar sales potential, Yee said.The analyst said he sees risks such as slowing infection rates in hot spots, low efficacy and competition from others by early 2021.In a fast enrollment/high incidence rate scenario, if the drug efficacy is 50%-60%-plus, the study would hit with a p-value less than 0.0001 by Oct. 29, he said. With a more conservative enrollment or infection rate, statistical significance could be hit study goals by mid-November to December, Yee said. Other variables that could push the timing are a more efficacious vaccine that could slow events; and the inability to meet the FDA guidance of statistical success that also includes the lower bound of the confidence interval of less than 30%, Yee said."Thus, there is a possibility the study achieves the 50-60% point estimate on efficacy but does not yet meet the "lower bound CI hurdle" which would necessitate the need for more patients and events to detect a difference."MRNA Price Action: At last check, Moderna shares were trading 3.51% higher to $76.70. Related Links:The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates Latest Ratings for MRNA DateFirmActionFromTo Jul 2020SVB LeerinkInitiates Coverage OnMarket Perform Jul 2020JP MorganDowngradesOverweightNeutral Jul 2020Chardan CapitalMaintainsBuy View More Analyst Ratings for MRNA View the Latest Analyst Ratings See more from Benzinga * The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings * Moderna Targeted By Chinese Hackers For Data Theft: Report * The Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 Funding(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/2PkraBZ

  • Microsoft and TikTok need each other

    Microsoft and TikTok need each otherMicrosoft and TikTok could prove to be each other's perfect match.

    from Yahoo Finance https://ift.tt/3fkIO2U

  • 5 things to watch on the ASX 200 on Tuesday

    Investment stock market Entrepreneur Business Man discussing and analysis graph stock market trading,stock chart concept

    On Monday the S&P/ASX 200 Index (ASX: XJO) started the week in a subdued fashion. The benchmark index finished the day roughly flat at 5,926.1 points.

    Will the market be able to do better than this on Tuesday? Here are five things to watch:

    ASX 200 expected to surge higher.

    It looks set to be a much more positive day for the ASX 200 on Tuesday. According to the latest SPI futures, the benchmark index is expected to open the day 84 points or 1.4% higher. This follows a positive start to the week on Wall Street, which saw the Dow Jones rise 0.9%, the S&P 500 climb 0.7%, and the Nasdaq index storm 1.5% higher. Strong gains by Apple and Microsoft helped drive U.S. markets higher.

    Reserve Bank meeting.

    This afternoon the Reserve Bank of Australia will meet to discuss the cash rate. At present, the market is pricing in a 57% probability of a rate cut to zero at the meeting. Although this means a cut is reasonably unlikely, it is in play. Especially given the recent strengthening of the Australian dollar versus the U.S. dollar.

    Oil prices push higher.

    Energy producers such as Beach Energy Ltd (ASX: BPT) and Woodside Petroleum Limited (ASX: WPL) could be on the rise today after oil prices pushed higher.  According to Bloomberg, the WTI crude oil price is up 1.2% to US$40.77 barrel and the Brent crude oil price has pushed 0.8% higher to US$43.88 a barrel. Positive economic data from Europe, Asia, and the United States helped support oil prices.

    Gold price hits record high.

    Gold miners including Evolution Mining Ltd (ASX: EVN) and Northern Star Resources Ltd (ASX: NST) will be on watch after the gold price pushed higher again. According to CNBC, the spot gold price is up 0.35% to US$1,992.8 an ounce. The precious metal hit a record high during overnight trade.

    BWP results.

    Bunnings Warehouse landlord BWP Trust (ASX: BWP) is scheduled to release its full year results this morning. In June the company revealed that it has been collecting rent largely as normal during the pandemic. In light of this, it expects to declare a second half distribution of 9.27 cents per unit. This will bring its full year distribution to 18.29 cents per unit, up 1% on the prior financial year. According to CommSec, the market expects a full year profit of $117 million.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 5 things to watch on the ASX 200 on Tuesday appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/31hASdI

  • Under The Bonnet, Lockheed Martin’s (NYSE:LMT) Returns Look Impressive

    Under The Bonnet, Lockheed Martin's (NYSE:LMT) Returns Look ImpressiveThere are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two…

    from Yahoo Finance https://ift.tt/33nQYoI

  • ‘A scary number’ of retail companies are facing bankruptcy amid the coronavirus pandemic

    'A scary number' of retail companies are facing bankruptcy amid the coronavirus pandemicThe retail sector in America continues to fall apart.

    from Yahoo Finance https://ift.tt/37WZWK0